프레스티지바이오파마

950210KOSPI

53.3 / 100

Reference Date: 2026-09-08

Financial Score16.5 / 40

News Sentiment18.8 / 25

Momentum6.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 2.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Prestige BioPharma is a biopharmaceutical company specializing in biosimilars and monoclonal antibody drug development. Its Herceptin biosimilar HD201 received a positive opinion from the European Medicines Agency (EMA) in 2024, while Avastin biosimilar HD204 and Humira biosimilar PBP1502 are in development. The company's pancreatic cancer treatment antibody drug PBP1510 holds patents in 13 countries, and its CTHRC1-targeting antibody drug PBP1710 is also in development.

Number of Employees

67people

Average Salary

53.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

130323.21Industry Average 15.000.0Point

8688.2x industry avg (risky)

PBR

—Industry Average 1.203.5Point

ROE

0.80Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

14.17Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1098.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -4.9% (improving, 2yr)

Detailed News Sentiment

8 totalPositive 6Neutral 2Negative 0Average Sentiment Score 75

Positive
프레스티지바이오파마 경영진 잇단 자사주 매입
프레스티지바이오파마 경영진의 자사주 매입은 회사의 바이오시밀러 상업화 및 R&D 역량에 대한 강한 자신감을 반영하며 긍정적인 시장 반응을 예상한다.
Positive
프레스티지바이오 "고상석 IDC대표, 4만5600주 매수"
고상석 IDC대표의 주식 매수로 회사의 중장기 성장에 대한 확신이 반영되어 긍정적인 시장 반응을 보임.
Positive
췌장암 신약 나왔다…19조 시장에 K-바이오 도전장
프레스티지바이오파마의 췌장암 신약이 FDA 승인을 받으며 글로벌 시장 진출 가능성이 높아져 긍정적 영향을 받음.

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 6,450Won52-week high 15,00052-week low 5,030

1-month return2.0Point

1m -2.27% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

11 totalPositive 1Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-09-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-01
Neutral최대주주등소유주식변동신고서2026-09-01
Positive[기재정정]단일판매ㆍ공급계약체결2026-08-25
Neutral주식등의대량보유상황보고서(일반)2026-08-19